Logo Image
|Podcasts|October 2, 2019

Pharm Exec Podcast Survey!

Hello all Pharm Exec podcasters! Thank you for taking the time to review our podcast survey. As you know, the podcast is about to start it’s 3rd year-and we’re really excited! We want to continue to bring you the latest and best guests this year to discuss business, strategy, R&D, and more in the pharma and biopharma industry.

Please click on the link below to complete a quick, 5-minute survey where we delve into how you listen to our episodes and what you’d most like to hear in 2020. The survey will close on November 8th, 2019.

Thank you again for your time, and we look forward to sharing more customized content in the future.

 

 

Complete the survey here!

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Pharmaceutical Executive daily
Pharmaceutical Executive Daily: FDA Approves New Indication for Kerendia
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Read more
Pharmaceutical executive daily
Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.
Read more